A Clinician’s Handbook for Childhood & Adult Immunizations in Georgia
Meningococcal Vaccination Recommendations
This table covers routine vaccination of preteens and teens, as well as catch-up vaccination of teens and young adults.
| Age of Patient | Vaccination History | Recommended MenACWY Schedule |
|---|---|---|
| Age 11 through 12 years | None | Give dose #1 of MenACWY. |
| Age 13 through 15 years | None | Give catch-up dose #1 of MenACWY. |
| Age 16 years | 1 prior dose | Give dose #2 of MenACWY. |
| Age 16 through 18 years | None | Give 1 dose of MenACWY. |
| Age 16 through 18 years | 1 prior dose when younger than 16 yrs | Give dose #2 of MenACWY. |
| Age 19 through 21 years | None, or 1 prior dose when younger than 16 yrs | Consider giving 1 dose of MenACWY. |
| First year college students living in residence halls | None, or 1 prior dose when younger than 16 yrs, or 1 prior dose since 16th birthday, but more than 5 yrs previously | Give 1 dose of MenACWY. |
Risk-based Recommendations for Persons with
Underlying Medical Conditions or Other Risk Factors
Travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic, people present during outbreaks caused by a vaccine serogroup,(2) and other people with prolonged increased risk for exposure (e.g., microbiologists routinely working with Neisseria meningitidis).
| Targeted Group by Age/or Risk Factor | Primary Dose(s)1 | Booster Dose(s)1 |
|---|---|---|
| For age 2 through 6 months | Give 3 doses of Menveo, 8 weeks apart, and a 4th dose at age 12–18 months. If possible, vaccination should begin at age 2 months. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains.(4) If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |
| For age 7 through 23 months who have not initiated a series of MenACWY | If age 7–8 months, initiate 2-dose series of Menveo(3) or, if age 9–23 months, give either Menveo or Menactra.(4) Separate the 2 doses by at least 12 weeks. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains.(4) If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |
| For age 2 years and older | Give 1 dose of any MenACWY vaccine.(4) | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains.(4) If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |
People with persistent complement component deficiencies
| Targeted Group by Age/or Risk Factor | Primary Dose(s)1 | Booster Dose(s)1 |
|---|---|---|
| For age 2 through 6 months | Give 3 doses of Menveo, 8 weeks apart, and a 4th dose at age 12–18 months. If possible, vaccination should begin at age 2 months. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |
| For age 7 through 23 months who have not initiated a series of MenACWY | If age 7–8 months, initiate 2-dose series of Menveo or, if age 9–23 months, give either Menveo or Menactra. Separate the 2 doses by at least 12 weeks. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |
| For ages 2 years and older | Give 2 doses of MenACWY (any vaccine), 8 weeks apart.4,7 | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter, as long as risk remains. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter, as long as risk remains. |
People with HIV infection or functional or anatomic asplenia (including sickle cell disease)
| Targeted Group by Age/or Risk Factor | Primary Dose(s)1 | Booster Dose(s)1 |
|---|---|---|
| For age 2 through 6 months | Give 3 doses of Menveo, 8 weeks apart, and a 4th dose at age 12–18 months. If possible vaccination should begin at age 2 months. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter. |
| For age 7 through 23 months who have not initiated a series of MenACWY-CRM | Give 2 doses of Menveo. Separate the 2 doses by at least 12 weeks. | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter. |
| For ages 2 years and older | Give 2 doses of MenACWY (any vaccine), 8 weeks apart. If using Menactra, give dose #1 at least 4 weeks after final dose of PCVl3 | If primary vaccination is completed before the 7th birthday: give one booster dose 3 years after primary series, then every 5 years thereafter. If primary vaccination is completed at age 7 years or older: give a booster dose every 5 years thereafter. |
Footnotes:
- If available, use the same vaccine product for all doses in the series given to infants, including the booster doses.
- Seek advice of local public health authorities to determine if vaccination is recommended.
- If initiating vaccination with Menveo in a child age 7 through 23 months, dose 2 should be given no younger than age 12 months.
4. If Menactra is to be administered to a child with increased risk for meningococcal disease, it should be given either before, at the same visit, or at least 6 months after Menveo and MenQuadfi can be given at any time before or after DTaP.
5. If child age 7 through 23 months will enter an endemic area in less than 3 months, give doses as close as 2 months apart.
6. Persistent deficiency of complement components C3, CS- C , properdin, factor D, or factor H caused by an immune system disorder or by taking a complement inhibitor (Soliris [eculizumab] or Ultomiris [ravulizumab]).
7. If the person has a history of l dose of MenACWY at the time of diagnosis with a high-risk condition for which a 2-dose pri- mary series is recommended, give dose 2, then boost every 5 years as long as risk remains.